Who is sponsoring NCT03782701?

NCT03782701 is sponsored by University of Miami.

What drugs are being tested in NCT03782701?

Interventions in NCT03782701: Brimonidine tartrate ophthalmic solution 0.025%, Sterile balanced saline solution.

What condition does NCT03782701 study?

NCT03782701 studies Eyelid Droop.

Is NCT03782701 still recruiting?

NCT03782701 is currently completed. Last updated 14 June 2021.

Are results published for NCT03782701?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-06-14 · How we verify

NCT03782701

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Lumify™ Eyedrops on Eyelid Position

Completed Phase 4 Results posted Last updated 14 June 2021

What this trial tests

Phase 4 trial testing Brimonidine tartrate ophthalmic solution 0.025% in Eyelid Droop in 43 participants. Completed in 1 April 2020.

Timeline

18 June 2019

Primary endpoint
1 April 2020

1 April 2020

Quick facts

Lead sponsor	University of Miami
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	18 June 2019
Primary completion	1 April 2020
Estimated completion	1 April 2020
Sites	1 location across United States

Drugs / interventions tested

Brimonidine tartrate ophthalmic solution 0.025% — full drug profile →
Sterile balanced saline solution

Conditions studied

Eyelid Droop — all drugs for Eyelid Droop →

Sponsor

University of Miami

Who can join

18 and older, any sex, with Eyelid Droop. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Palpebral Fissure Height Primary · Baseline, 5, 15 and 30 minutes after application

Objective measurement of distance between inner margin of upper and lower eyelids from clinical photographs.

Baseline

Group	Value	95% CI
Lumify Eye Drop	9.64	± 1.71
Saline Solution Eye Drop	9.66	± 1.62

5 minutes after application

Group	Value	95% CI
Lumify Eye Drop	9.92	± 1.33
Saline Solution Eye Drop	9.96	± 1.35

15 minutes after application

Group	Value	95% CI
Lumify Eye Drop	9.85	± 1.42
Saline Solution Eye Drop	9.96	± 1.40

30 minutes after application

Group	Value	95% CI
Lumify Eye Drop	9.86	± 1.32
Saline Solution Eye Drop	9.84	± 1.26

Intraocular Pressure Secondary · Baseline, 5, 15 and 30 minutes after application

Measurement of intraocular pressure using handheld Tono-Pen(tm) tonometer

Baseline

Group	Value	95% CI
Lumify Eye Drop	16.54	± 3.63
Saline Solution Eye Drop	16.70	± 3.42

30 minutes after applciation

Group	Value	95% CI
Lumify Eye Drop	15.54	± 3.30
Saline Solution Eye Drop	15.58	± 2.99

Eye Redness Secondary · Baseline, 5, 15 and 30 minutes after application

Eye redness will be reported as the number of participants achieving a score of ocular redness from clinical photographs as 0 (none), 1 (mild), 2 (moderate) and 3 (severe).

Baseline - None

Group	Value	95% CI
Lumify Eye Drop	24
Saline Solution Eye Drop	25

Baseline - Mild

Group	Value	95% CI
Lumify Eye Drop	17
Saline Solution Eye Drop	16

Baseline - Moderate

Group	Value	95% CI
Lumify Eye Drop	2
Saline Solution Eye Drop	2

Baseline - Severe

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	0

5 minutes after application - None

Group	Value	95% CI
Lumify Eye Drop	38
Saline Solution Eye Drop	6

5 minutes after application - Mild

Group	Value	95% CI
Lumify Eye Drop	4
Saline Solution Eye Drop	19

5 minutes after application - Moderate

Group	Value	95% CI
Lumify Eye Drop	1
Saline Solution Eye Drop	17

5 minutes after application - Severe

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	1

Eye Discomfort Secondary · Baseline, 5, 15 and 30 minutes after application

Eye discomfort will be reported as the number of participants reporting subjective ocular discomfort score from 0 (none), 1 (mild), 2 (mild) and 3 (severe).

Baseline - None

Group	Value	95% CI
Lumify Eye Drop	43
Saline Solution Eye Drop	43

Baseline - Mild

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	0

Baseline - Moderate

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	0

Baseline - Severe

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	0

5 minutes after application - none

Group	Value	95% CI
Lumify Eye Drop	40
Saline Solution Eye Drop	38

5 minutes after application - mild

Group	Value	95% CI
Lumify Eye Drop	3
Saline Solution Eye Drop	4

5 minutes after application - moderate

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	0

5 minutes after application - severe

Group	Value	95% CI
Lumify Eye Drop	0
Saline Solution Eye Drop	1

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 30 minutes. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Lumify Eye Drop

Serious: 0/43 (0%)

Deaths: 0/43

Saline Solution Eye Drop

Serious: 0/43 (0%)

Deaths: 0/43

Other adverse events (3 terms — click to expand)

Reaction	System	Lumify Eye Drop	Saline Solution Eye Drop
Eye Dryness	Eye disorders	—	—
Eye Pain	Eye disorders	—	—
Eye Itchiness	Eye disorders	—	—

Data from ClinicalTrials.gov NCT03782701 adverse events section.

Sponsor's own description

The purpose of the research is to see if Lumify™ has an effect on eyelid position.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03782701 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 14 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03782701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing